Lupin Q2 FY27 Results: 14% Sales Growth Amid Margin Contraction
Lupin Ltd 路 Investor Presentation 路 04 Nov 2026, 7:22 am
Lupin Q2 FY27 Results: 14% Sales Growth Amid Margin Contraction Lupin reported net sales of INR 77,855 mn for Q2 FY27, up 14.0% YoY but down 5.3% QoQ. EBITDA declined 8.4% YoY to INR 19,574 mn, with EBITDA margin contracting to 25.1% from 31.3% in Q2 FY26. Net income fell 21.8% YoY to INR 11,553 mn. India sales grew 15% YoY to INR 23,836 mn, while US sales rose 10% YoY to INR 31,696 mn ($317 mn, down 13% QoQ). The balance sheet remained net cash with net debt-to-equity at (0.14).
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
